Prospects and Challenges for the Commercialization of Biosimilars: Perspectives from the EU, Japan, and the US

Joanna Brougher
Owner & Principal, BioPharma Law Group PLLC Editor-in-Chief, Journal of Commercial Biotechnology

DOI:https://doi.org/10.5912/jcb751

Abstract:

With many blockbuster biologic drugs coming off patent in the next couple of years, biosimilars are making significant breakthroughs in cost-effective biologic therapies. The global market for biosimilars is expected to increase nearly 30 fold from $1.3 billion in 2013 to $35 billion by 2020. To promote biosimilar development and commercialization in the U.S., the Biosimilars Act was signed into law in 2010 to establish an abbreviated pathway by which the FDA could approve biosimilar versions of previously licensed biological products. Since its enactment, two biosimilars have been approved in the U.S. This Article will discuss key aspects of the U.S., the EU and Japanese approval pathways and will explore their likely impact on the commercialization of biosimilar medicines.  

Keywords:Biosimilars Act ,biosimilars ,Biologics ,Biologics Price Competition and Innovation Act ,en ,